| name | endo-hirsutism-oc-initial-therapy-not-seeking-fertility |
| description | Suggest oral combined estrogen–progestin contraceptives as initial therapy for most premenopausal women with patient‑important hirsutism who are not seeking fertility. Consider this approach when hirsutism persists despite cosmetic measures (shaving, plucking, waxing) and the patient desires pharmacological treatment. |
Use oral contraceptives as initial therapy for most non‑fertility‑seeking women
STEP 1 — Gather Information
Record Ferriman–Gallwey score, assess whether hirsutism is patient‑important despite cosmetic measures, determine fertility desire, and collect medical history for venous thromboembolism (VTE) risk (age, BMI, smoking, hypertension, migraine with aura, personal/family VTE) and current medications.
STEP 2 — Rule In / Rule Out
If the patient is seeking pregnancy or planning conception → OC contraindicated; consider non‑estrogenic alternatives (e.g., antiandrogen with reliable contraception or direct hair removal). If not seeking fertility → proceed to assess OC safety.
STEP 3 — Classify or Stratify
Stratify VTE risk: low risk (age <39, BMI <30 kg/m², no smoking, no hypertension, no migraine with aura, no personal/family VTE) vs increased risk (any of: age ≥39, BMI ≥30, smoking, hypertension, migraine with aura, prior VTE, thrombophilia).
STEP 4 — Decide
Low risk: prescribe any combined OC containing ethinyl estradiol 20‑35 mcg and a progestin of patient choice. Increased risk: prescribe OC with ethinyl estradiol 20 mcg and a low‑risk progestin (e.g., norgestimate, gestodene, desogestrel) per Table 2. Schedule follow‑up in 3‑6 months to evaluate hirsutism improvement; if suboptimal after ≥6 months, add an antiandrogen.
Clinical Guardrails / Mimics / Pitfalls
Do not use OC in women seeking pregnancy, with active VTE, uncontrolled hypertension, migraine with aura, smoking >35 years, or known thrombophilia. Avoid antiandrogen monotherapy without reliable contraception. Do not rely on OC alone for rapid improvement in severe hirsutism; add antiandrogen only after ≥6 months of suboptimal response. Monitor blood pressure, weight, and mood during OC use.
Concrete Clinical Example
A 28‑year‑old woman presents with hirsutism (Ferriman–Gallwey 12) that is patient‑important despite daily shaving; she does not desire pregnancy, has BMI 22, no hypertension, no smoking, and no personal/family VTE. She is prescribed a combined OC with ethinyl estradiol 20 mcg and desogestrel. At 4‑month follow‑up she reports reduced hair growth and satisfaction; therapy is continued.
Source: Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2018, doi:10.1210/jc.2018-00241
